ANN ARBOR, Mich. – April 29, 2013 – Lycera Corp., a biopharmaceutical company pioneering the development of breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Bruce A. Goldsmith, Ph.D., as chief business officer. In this new position, Dr. Goldsmith will work as part of the executive team to implement the company’s… Read More

ANN ARBOR, Mich. – April 1, 2013 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Laura L. Carter, Ph.D. to vice president, biology. “I am pleased to welcome Dr. Carter to the Lycera team,” said Kathleen M. Metters, Ph.D., Lycera… Read More

Collaboration to Focus Strategically on Novel Treatments for Autoimmune Disease ANN ARBOR, Mich. – February 12, 2013 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing breakthrough oral medicines to treat autoimmune diseases, today announced a collaboration agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and… Read More